Voiding Dysfunction

Transitional Zone Index and Intravesical Prostatic Protrusion in Benign Prostatic Hyperplasia Patients: Correlations according to Treatment Received and Other Clinical Data

Tao Huang, Jun Qi, YongJiang Yu, Ding Xu, Yang Jiao, Jian Kang, YunKai Zhu1, YaQing Chen1
Departments of Urology, 1Ultrasonography, Xin Hua Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Purpose: The aim of this research was to assess the value of the transitional zone index (TZI) and intravesical prostatic protrusion (IPP) from transrectal ultrasonography in evaluating the severity and progression of disease by analyzing the relationship between the 2 parameters and symptoms, clinical history, and urodynamics in benign prostatic hyperplasia (BPH) patients undergoing different treatment.

Materials and Methods: A total of 203 patients receiving medication and 162 patients who underwent transurethral resection of the prostate because of BPH were enrolled in this retrospective analysis. The clinical history and subjective and objective examination results of all patients were recorded and compared after being classified by TZI and IPP level. Linear regression was used to find correlations between IPP, TZI, and urodynamics.

Results: The 2 parameters were found to differ significantly between patients receiving medication and patients undergoing surgical therapy (p < 0.05). PSA, maximum flow rate (Qmax), detrusor pressure at Qmax (PdetQmax), and the bladder outlet obstruction index (BOOI) differed according to various TZI levels (p < 0.05). In addition, the voiding symptom score, Qmax, and BOOI of subgroups with various IPP levels were also significantly different (p < 0.05). Both TZI and IPP had significant effects on Qmax, BOOI, and PdetQmax (p < 0.05) and the incidence of acute urinary retention (p=0.000).

Conclusions: The results demonstrated that both TZI and IPP had favorable value for assessing severity and progression in patients with BPH. Further studies are needed to confirm whether the two parameters have predictive value in the efficacy of BPH treatment and could be considered as factors in the selection of therapy.

Key Words: Benign prostatic hyperplasia; Medication; Transurethral resection of the prostate; Ultrasonography; Urodynamics

INTRODUCTION

Benign prostatic hyperplasia (BPH) is found in over half of 60-year-old men and in almost all 80-year-old men who develop bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) [1]. BOO is the initial pathophysiological change caused by an enlarged adenoma and is followed by detrusor overactivity (DO) or underactivity (DUA). The degree of BOO is an important factor that can reflect the severity of disease and that can aid in choosing a treatment method as well as in measuring the outcome of the treatment. It has been shown that one third of male patients with LUTS do not have definite BOO and that 5 to 35% of the patients with LUTS and undefined BOO do not have favorable symptom recovery after transurethral resection of the prostate (TURP) [2-7]. Relevant examinations ranging from serum prostate-specific antigen (PSA) to urodynamics can all reflect different aspects of the se-
verity of BPH. Urodynamics is the only method, however, that can quantify the degree of BOO and the status of detrusor contractility. Therefore, guidelines from the International Scientific Committee and the American Urological Association on the management of BPH both recommend the use of urodynamics to evaluate BPH patients considered as candidates for invasive therapy [8]. However, the routine use of preoperative urodynamics is still a controversial point in published articles because of the invasiveness and high costs of the method [9]. In this research, we attempted to determine whether other parameters could be used to measure the severity of BOO through less-invasive or noninvasive examinations by analyzing correlations among parameters from clinical history, symptoms, ultrasonography, and urodynamics.

MATERIALS AND METHODS

This retrospective analysis was conducted on patients with BPH who had received either medication or surgical treatment at this hospital between May 2010 and June 2011. The therapeutic decision for TURP was based on both clinical assessment and the patient’s desire. All patients were evaluated with the International Prostate Symptom Score (IPSS, including the total score; subtotal score of storage symptoms comprising the summation of nocturia, urgency, and an increased frequency score; and subtotal score of voiding symptoms comprising the summation of hesitancy, intermittency, and weak stream score) and quality of life (QoL) questionnaires in addition to undergoing basic clinical evaluations (medical history, physical examination, urinalysis, and renal function assessment) before treatment. Free flowmetry measurement was performed for all patients with the result being adopted when the voiding volume was more than 150 ml. Urodynamics was performed only for patients needing surgery by use of a multichannel system (UDS64-III, Laborie Co., Quebec, Canada). First, water-Filling cystometry was done with the patients in the supine position with the use of a transurethral 12 Fr double-lumen catheter and the simultaneous monitoring of rectal pressure. Filling was performed at a rate of 50 ml/min with normal saline and was stopped if the patient had a strong desire to void. Pressure flow study (PFS) was then performed by asking the patients to void in an upright position with a suprapubically placed 6 Fr cystostomy tube to monitor the bladder pressure. Maximum urinary flow (Qmax) and pressure of the detrusor at Qmax (PdetQmax) were recorded. The bladder outlet obstruction index (BOOI, by “PdetQmax-Qmax”) and the bladder contractility index (by “PdetQmax+5Qmax”) were then calculated by use of equations from the ICS [10]. Total prostate volume (TPV), transitional zone volume (TZV), intra-vesical prostatic protrusion (IPP), and post-voiding residual (PVR) were measured by transrectal ultrasonography (TRUS) with the transitional zone index (TZI, by “TZV/TPV”) being calculated for all patients. The exclusion criteria for enrolled subjects were 1) BOOI less than 20 or Qmax more than 20 ml/s, 2) disease with BOO other than BPH, 3) history of prostatic or urethral surgery, 4) diagnosed carcinoma of the prostate or bladder, 5) known bladder stones or neurogenic bladder dysfunction, and 6) not having taken standard medication involving both alpha-adrenergic blockers and 5-alpha-reductase inhibitors for over 6 months.

The relevant clinical data of the subjects were recorded and classified by degree of IPP (<10 mm, 10 to 20 mm, and >20 mm) and TZI value (<0.5, 0.5 to 0.7, and >0.7). All quantitative variables were tested for the type of distribution by use of the one-sample Kolmogorov-Smirnov test. Univariate analyses including one-way analysis of variance and Kruskal-Wallis test were used for variables with normal or skewed distributions, respectively, to assess the differences between patients receiving drug therapy and those undergoing surgical therapy and between patients with different degrees of IPP and TZI values. The χ²-test was used for categorical variables to identify whether there were different incidences of acute urinary retention (AUR) influenced by different IPP or TZI grade. Finally, bivariate correlation and multiple regression analysis were used to assess correlations between parameters from TRUS and PFS. All analyses were performed by using the routines of the IBM SPSS ver. 19.0 (IBM Co., New York, NY, USA), and statistical significance was defined as a p-value less than 0.05. The research attained ethical approval from the ethics committee of Xin Hua Hospital, and all subjects gave written informed consent.

RESULTS

A total of 365 patients were enrolled in the research study, with 203 patients receiving medication and the remainder having undergone TURP. The clinical data of all subjects were classified according to therapy and degree of IPP and TZI and are listed in Tables 1 and 2. Univariate analyses showed significant differences in the total, storage, and voiding scores of the IPSS; QoL score; TPV; TZV; TZI; IPP; and Qmax between the therapy groups (p < 0.05). Baseline total prostate-specific antigen, TPV, TZV, IPP, Qmax, PdetQmax, and BOOI classified by different degrees of TZI were also found to be significantly different (p < 0.05). Differences were also found in the voiding symptom score, TPV, TZV, TZI, Qmax, and BOOI classified by degree of IPP (p < 0.05). IPP (p = 0.000) and TZI (p = 0.000) both had statistically significant effects on the cause of AUR (Table 2) by χ²-test. The bivariate correlation analysis of parameters from symptom score, TRUS, and urodynamics showed significant correlations between TZI and Qmax (r = -0.887, p = 0.001), PdetQmax (r = 0.725, p = 0.028), and BOOI (r = 0.508, p = 0.029) and between IPP and voiding symptom score (r = 0.353, p = 0.033), Qmax (r = 0.852, p = 0.014), and BOOI (r = 0.469, p = 0.042). Multiple regression analysis in the subjects who underwent TURP showed that both TZI and IPP had significant correlations with Qmax and BOOI, whereas TZI had a significant correlation with PdetQmax.
### TABLE 1. Comparisons of baseline characteristics in patients between different methods of therapy

| Characteristic          | Overall (n=365) | Medication (n=203) | Surgery (n=162) | p-value |
|-------------------------|----------------|-------------------|----------------|---------|
| Age (yr)                | 66.8±9.4       | 63.7±5.8          | 73.3±4.2       | 0.066   |
| T-PSA (ng/ml)           | 5.1 (3.2-23.9) | 4.0 (3.2-9.8)     | 5.3 (1.4-18.7) | 0.146   |
| Total IPSS              | 12.2±7.1       | 9.3±5.5           | 18.6±4.1       | 0.021   |
| Storage IPSS            | 6.9±3.3        | 6.5±3.4           | 7.2±7.0        | 0.053   |
| Voiding IPSS            | 5.8±3.9        | 3.0±1.8           | 8.1±4.2        | 0.007   |
| QOL score               | 3.6±2.6        | 2.5±1.2           | 4.1±8.4        | 0.029   |
| TPV (g)                 | 43.0±11.7      | 36.8±14.5         | 50.6±27.3      | 0.012   |
| TZV (g)                 | 26.6±19.0      | 21.5±18.2         | 35.4±22.7      | 0.008   |
| Presence of AUR history | 65 (17.8)      | 21 (10.3)         | 44 (27.2)      | 0.000   |

Values are presented as mean±SD, median (range) or number (%).

- T-PSA, total prostate-specific antigen; IPSS, International Prostate Symptom Score; QOL, quality of life; TPV, total prostate volume; TZV, transitional zone volume; TZI, transitional zone index; IPP, intravesical prostatic protrusion; PRV, postvoiding residual volume; Qmax, maximum urinary flow; PdetQmax, pressure of detrusor at Qmax; BOOI, bladder outlet obstruction index; BCI, bladder contractility index; AUR, acute urinary retention.

### TABLE 2. Comparisons of baseline characteristics in patients according to TZI and IPP

| Characteristic          | TZI < 0.5 (n=133) | 0.5-0.7 (n=108) | 0.7-1 (n=124) | p-value |
|-------------------------|-------------------|-----------------|---------------|---------|
| Age (yr)                | 61.3±7.1          | 63.0±9.27       | 64.0±8.32     | 0.291   |
| T-PSA (ng/ml)           | 3.5 (0.3-13.3)    | 4.3 (2.0-23.9)  | 7.4           | 0.048   |
| Total IPSS              | 11.6±5.9          | 10.8±8.2        | 14.2±7.5      | 0.158   |
| Storage IPSS            | 6.4±4.7           | 6.1±4.0         | 7.2±6.2       | 0.084   |
| Voiding IPSS            | 4.2±5.8           | 6.1±4.5         | 6.6±3.2       | 0.055   |
| QOL score               | 3.1±1.1           | 2.8±1.3         | 3.9±1.4       | 0.106   |
| TPV (g)                 | 29.9±24.1         | 43.8±26.5       | 70±58.9       | 0.029   |
| TZV (g)                 | 17.7±10.2         | 23.4±18.8       | 41.9±30.6     | 0.014   |
| Presence of AUR history | NS                | NS              | 40.5±37.0     | 0.036   |

### Surgical patients

| Characteristic          | < 0.5 (n=71) | 0.5-0.7 (n=48) | > 0.7 (n=43) | p-value |
|-------------------------|--------------|----------------|--------------|---------|
| PdetQmax (cm H2O)       | 65.2±39.0    | 74.6±40.6      | 83.8±54.5    | 0.022   |
| BOOI                    | 50.9±22.8    | 60.4±20.8      | 72.3±25.1    | 0.028   |
| BCI                     | 126.1±33.8   | 129.8±35.4     | 118.7±28.0   | 0.164   |

Values are presented as mean±SD, median (range) or number (%).

- TZI, transitional zone index; IPP, intravesical prostatic protrusion; T-PSA, total prostate-specific antigen; IPSS, International Prostate Symptom Score; QOL, quality of life; TPV, total prostate volume; TZV, transitional zone volume; IPP, intravesical prostatic protrusion; PRV, postvoiding residual volume; Qmax, maximum urinary flow; AUR, acute urinary retention; PdetQmax, pressure of detrusor at Qmax; BOOI, bladder outlet obstruction index; BCI, bladder contractility index.

*a*: Student’s t-test, *b*: Mann-Whitney U test, *c*: Fisher’s exact test.
DISCUSSION

The pathophysiology of BPH is complex. Prostatic adenoma enlargement increases urethral resistance and leads to BOO, further resulting in compensatory changes in bladder function. However, the elevated detrusor pressure required to maintain urinary flow in the presence of increased outflow resistance occurs at the expense of normal bladder storage function, which is the source of DO. With the continuation of obstruction, decompensation of the detrusor and DUA will eventually take place. The degree of BOO is correlated with the severity of obstruction-relevant symptoms, and the recovery of BOO is used to evaluate the efficacy of treatment of BPH. Furthermore, the baseline degree of BOO was recently found to influence the outcome of treatment. Research has shown that patients with BOO have better outcomes from TURP than those without BOO [11-14]. One research study showed that patients with BOO will still have a favorable surgical outcome even if they have DO or DUA [14]. Therefore, some hospitals use urodynamics as a routine preoperative examination to confirm whether the candidates have explicit BOO and good detrusor contractility. However, urodynamic study is not totally innocuous, with significant evidence of discomfort and urinary infections associated with performing the examination, as well as imposing additional cost to the patient or to the institution. For this reason, some research has been initiated to find less-invasive or non-invasive examinations for evaluating the degree of BOO.

IPP measured as the shortest distance connecting the protruded end of the prostate into the bladder based on the bladder neck in the sagittal plane reflects the maximum longitudinal length of the prostate and may help in assessing the obstructive level of the prostate. Nose et al. [15] first studied the correlation between IPP and the BOOI in 30 male outpatients in 2005 and found that IPP grading correlated well with the BOOI. Keqin et al. [16] analyzed 206 BPH patients classified by different IPP grade and found that the IPP value positively correlated with TPV, PSA, PVR, Qmax, PdetQmax, and BOOI as well as the incidence of AUR, bladder trabeculation, detrusor overactivity, and low bladder compliance. Ku et al. [17] analyzed 260 men with LUTS and found that the BOOI was higher in patients with apparent IPP than in those without. The TZI calculated as TZV divided by TPV may also correlate with the obstructive level because higher volumes of the transition zone will result in harder pressure on the urethra. Kaplan et al. [18] evaluated 61 men with symptomatic BPH and found a significant correlation between TZI and symptoms, Qmax, and PdetQmax. Wang et al. [19] analyzed 116 BPH patients and found that TZI and TZV were both positively correlated with BOOI and IPSS. Milonas et al. [20] reported that lower TZI was an independent predictor of ineffective surgical outcome. In the present study, we found significant correlations in surgical patients between both TZI and IPP with parameters reflecting the level of BOO, such as Qmax, PdetQmax, and BOOI. These results are consistent with the results of former research and suggest that TZI and IPP may be appropriate parameters in diagnosing and classifying BOO. For a long period, TURP has been the gold standard surgical procedure based on the concept of removing the whole enlarged adenoma involved in static and dynamic urethral obstruction. However, the development of medication such as alpha-adrenergic blockers and 5-alpha-reductase inhibitors has decreased the progression of BPH and the operation rate in patients in recent years. However, some patients cannot achieve favorable recovery from drug therapy and need a surgeon to relieve the symptoms. The patients needing surgical therapy in our research were found to have higher values of both IPP and TZI than the patients needing only drug therapy. This result suggests that IPP and TZI could measure the disease progression in BPH patients receiving medication and might have predictive value for medication efficacy. Higher IPP grade was found to correlate with higher voiding symptom score, which demonstrated that IPP could reflect the severity of BPH from not only an objective aspect but also a subjective aspect. AUR is one of the most serious complications of BPH and an indication for surgical intervention. This research has found positive correlations.

### Table 3. Model summary of multiple linear regression with the parameters from TRUS and urodynamics

|       | Qmax | PdetQmax | BOOI |
|-------|------|----------|------|
|       |       | Standardized coefficients | p-value | Standardized coefficients | p-value | Standardized coefficients | p-value |
| TPV   | -0.729 | 0.490 | 0.136 | 0.052 | 0.394 | 0.159 |
| TZV   | -0.747 | 0.502 | 0.017 | 0.077 | 0.560 | 0.122 |
| TIZ   | -0.630 | 0.004 | 0.809 | 0.013 | 0.702 | 0.028 |
| IPP   | -0.821 | 0.038 | 0.524 | 0.059 | 0.028 | 0.043 |
| PRV   | -0.058 | 0.223 | 0.021 | 0.039 | 0.142 | 0.640 |
| R Square | 0.955 | 0.943 | 0.826 |

TRUS, transrectal ultrasonography; Qmax, maximum urinary flow; PdetQmax, pressure of detrusor at Qmax; BOOI, bladder outlet obstruction index; TPV, total prostate volume; TZV, transitional zone volume; TIZ, transitional zone index; IPP, intravesical prostatic protrusion; PRV, postvoiding residual volume.

Korean J Urol 2012;53:253-257
between not only IPP but also TZI and the incidence of AUR, which further suggests that these 2 factors might be used to predict the progression of BPH and the possibility of undergoing surgical therapy.

CONCLUSIONS

In general, this research investigated TZI and IPP from TRUS in BPH patients and found positive correlations between these indexes and symptoms, BOO level, and the incidence of AUR. TZI and IPP were also found to differ significantly between BPH patients receiving medication and those undergoing surgical therapy. The results demonstrated that the two parameters had favorable value for assessing severity and progression in patients with BPH. However, this research was retrospective only, with inevitable bias from subject selection and follow-up time. Therefore, more prospective research should be launched to investigate the predictive value of the two parameters for the progression and treatment efficacy of BPH.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGEMENTS

The study was funded by Surgical outcome of Large Sample BPH Patients Research, which was sponsored by the Science and Technology Commission of Shanghai (project number: 09411950100), and Influence of SNPs in Drug Therapy of Large Sample BPH Patients, which was sponsored by the NSFC (Natural National Science Foundation of China, project number: 81070600). Relevant staffs from the Departments of Urology, Urography of Xin Hua Hospital have given much help in the gathering of data. Special thanks to the department of statistics in Shanghai Jiao Tong University School of Medicine for help in data processing.

REFERENCES

1. Harding C, Robson W, Drinnan M, Sajeel M, Ramsden P, Griffiths C, et al. Predicting the outcome of prostatectomy using noninvasive bladder pressure and urine flow measurements. Eur Urol 2007;52:186-92.
2. Kuo HC. Clinical prostate score for diagnosis of bladder outlet obstruction by prostate measurements and uroflowmetry. Urology 1999;54:90-6.
3. Rodrigues P, Lucon AM, Freire GC, Arap S. Urodynamic pressure flow studies can predict the clinical outcome after transurethral prostatic resection. J Urol 2001;165:499-502.
4. Yalla SV, Sullivan MP, Lecamwasam HS, DuBeau CE, Vickers MA, Cravalho EG. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 1995;153(3 Pt 1):674-9.
5. Kaplan SA, Bowers DJ, Te AE, Olsson CA. Differential diagnosis of prostatism: a 12-year retrospective analysis of symptoms, urodynamics and satisfaction with therapy. J Urol 1996;155:1305-8.
6. Bruskewitz RC, Larsen EH, Madsen PO, Darflinger T. 3-year follow-up of urinary symptoms after transurethral resection of the prostate. J Urol 1986;136:613-5.
7. Neal DE, Ramsden PD, Sharples L, Smith A, Powell PH, Styles RA, et al. Outcome of elective prostatectomy. BMJ 1989;299:762-7.
8. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):530-47.
9. van Venrooij GE, van Melick HH, Boon TA. Comparison of outcomes of transurethral prostate resection in urodynamically obstructed versus selected urodynamically unobstructed or equivocal men. Urology 2003;62:672-6.
10. Liddle D, Hölter N, van Mastrigt R, Rollema HJ, Spängberg A, Gleason D. Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. International Continence Society Subcommittee on Standardization of Terminology of Pressure-Flow Studies. Neurourol Urodyn 1997;16:1-18.
11. Seki N, Takei M, Yamaguchi A, Naito S. Analysis of prognostic factors regarding the outcome after a transurethral resection for symptomatic benign prostatic enlargement. Neurourol Urodyn 2006;25:428-32.
12. Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S. Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 2006;67:306-10.
13. Han DH, Jeong YS, Choo MS, Lee KS. The efficacy of transurethral resection of the prostate in the patients with weak bladder contractility index. Urology 2008;71:657-61.
14. Tanaka Y, Masumori N, Itoh N, Furuya S, Ogura H, Tsukamoto T. Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity? Int J Urol 2006;13:1398-404.
15. Nose H, Foo KT, Lim KB, Yokoyama T, Ozawa H, Kumon H. Accuracy of two noninvasive methods of diagnosing bladder outlet obstruction using ultrasonography: intravesical prostatic protrusion and velocity-flow video urodynamics. Urology 2003;65:493-7.
16. Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology 2007;70:1096-9.
17. Ku JH, Ko DW, Cho JY, Oh SJ. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms. Urology 2010;75:1467-71.
18. Kaplan SA, Te AE, Pressler LB, Olsson CA. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 1995;154:1764-9.
19. Wang Y, Pei F. Clinical significance of the parameters of prostate volume measured by TRUS in evaluating bladder outlet obstruction. Zhonghua Nan Ke Xue 2003;9:522-3, 526.
20. Milonas D, Safaris V, Jevitals M. Transition zone index and bothersomeness of voiding symptoms as predictors of early unfavorable outcomes after transurethral resection of prostate. Urol Int 2008;81:421-6.